Immunotherapy, an emerging and innovative approach to treating severe asthma, has shown significant potential in recent years. Unlike traditional asthma treatments that primarily focus on managing symptoms, immunotherapy targets the underlying immune system mechanisms contributing to asthma. This therapeutic strategy involves the use of biological agents that specifically modulate the immune response, offering a more personalized and precise treatment for individuals with severe asthma. One of the primary forms of immunotherapy for asthma involves the use of monoclonal antibodies that target specific components of the immune system. For instance, omalizumab is a monoclonal antibody that binds to immunoglobulin E (IgE), a key player in allergic reactions. By inhibiting the activity of IgE, omalizumab can reduce allergic inflammation and prevent asthma exacerbations in patients with severe allergic asthma.